CMV DNA linearity panel, 4/14
April 2014—SeraCare Life Sciences is offering a nine-member panel made from serial dilutions of a cultured virus with established reactivity for CMV DNA called the CMV DNA AccuSpan Linearity Panel.
Webinars and Sponsored Roundtables — Register Now
Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
Middleware user satisfaction, 4/14
April 2014—Siemens Healthcare Diagnostics’ CentraLink Data Management System achieved the highest rating for overall user satisfaction, according to the Middleware Market Monitor, a report published by Information Dynamics. The report reviews the current use of middleware solutions in the main hospital clinical laboratory and tracks changes in product usage or applications.
Benchtop chemistry analyzer, 4/14
April 2014—Vital Diagnostics launched the Eon 300 benchtop scalable chemistry analyzer for small to midsize physician office labs, satellite labs, and small hospital labs.
Multianalyte quality controls, 4/14
April 2014—Bio-Rad Laboratories has a comprehensive line of multianalyte quality controls now available in Siemens Dimension Vista vials for use on Siemens Dimension Vista Intelligent Lab Systems.
New CLSI editions: M100-S24, eM100, 4/14
April 2014—The Clinical and Laboratory Standards Institute released a new edition of its document M100-S24: Performance Standards for Antimicrobial Susceptibility Testing; Twenty-Fourth Informational Supplement, which provides updated tables for the CLSI antimicrobial susceptibility testing standards M02-A11, M07-A9, and M11-A8.
Horizon, Desktop Genetics to collaborate, 4/14
April 2014—Horizon Discovery entered into a collaboration agreement with Desktop Genetics for development of a CRISPR design platform. Horizon will use the platform to identify the best guide-RNAs in the human genome for each gene editing task, as part of its GENESIS suite of gene editing technologies.
Nuclea partners with AccuGenomics, Nuvera, 4/14
April 2014—Nuclea signed development deals with AccuGenomics and Nuvera Biosciences that will include validating two new assays in the treatment of chronic myeloid leukemia and breast cancer.
Colorectal cancer screening kits, 4/14
April 2014—EntroGen expanded its line of colorectal cancer screening products to include the EntroGen K-Ras and N-Ras Mutation Analysis kits. The kits are updated to include coverage for exon 2, 3, and 4 mutations in both genes. The company obtained a CE IVD mark for these products.
Horizon-Haplogen agreement, 4/14
April 2014—Horizon Discovery signed a worldwide distribution agreement with Haplogen in which customers can access, directly from Horizon, Haplogen’s Haploid Gene Trap Mutant Collection of isogenic human cell lines deficient for the expression of single genes. This is the first time Horizon will distribute another company’s products.
Automated pipetting systems, 4/14
April 2014—Eppendorf North America added five models to its epMotion range of automated pipetting systems. The epMotion 5075 system uses Eppendorf’s epBlue software and an intuitive software assistant concept that can be easily programmed and requires only initial training for new users.